Literature DB >> 23529576

Combination therapy to prevent cardiovascular disease: slow progress.

Richard Smith1, Tara McCready, Salim Yusuf.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529576     DOI: 10.1001/jama.2013.3180

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

Review 1.  Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe?

Authors:  Vanessa Selak; Ruth Webster
Journal:  Ther Adv Drug Saf       Date:  2017-12-20

Review 2.  Lifestyle Modification in Secondary Prevention: Beyond Pharmacotherapy.

Authors:  Jenna Brinks; Amy Fowler; Barry A Franklin; Jassu Dulai
Journal:  Am J Lifestyle Med       Date:  2016-07-08

Review 3.  Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill.

Authors:  M Lafeber; W Spiering; F L J Visseren; D E Grobbee
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

4.  Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study.

Authors:  Nuri Kodaman; Melinda C Aldrich; Rafal Sobota; Folkert W Asselbergs; Kwabena A Poku; Nancy J Brown; Jason H Moore; Scott M Williams
Journal:  PLoS One       Date:  2016-10-12       Impact factor: 3.240

Review 5.  Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine.

Authors:  Dean Ho; Chung-Huei Katherine Wang; Edward Kai-Hua Chow
Journal:  Sci Adv       Date:  2015-08-21       Impact factor: 14.136

6.  Role of angiopoietin-2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusion-induced injury in H9c2 cardiomyocytes.

Authors:  Shuoqiang Hu; Shujun Cao; Jinghua Liu
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.